salmon fishing, page-4

So why has Oxyc. progress been postponed to a fairly hazy future date?

I shall certainly ask the company Dougal. I don't believe it has been held back because of what's gone wrong in the recent trial, rather than by what has gone unexpectedly right, I guess you could say. The oxy patch we were originally progressing was intended only for chronic nociceptive pain treatment. Now it's been found that it also seems suitable for chronic neuropathic pain treatment. Which way to go at this latest juncture? How long will further testing and the decision-making process take?

This issue of junctures in research when unexpected results arise was raised by Dr El-Tamimy when we visited the POH facility in April. Multiple people and factors he said ultimately inform the decisions as to how, where and when to proceed. In fact, this was how TPM drug delivery came about, by my understanding. Unexpected results came up, further tests were run, a decision was made and BINGO... new direction.

Another analogy is, let's say I have $50 000 to invest and have just completed my due diligence on a company which I've decided stacks up as a fantastic investment. Just as I'm about to invest, I come across another company which looks like it might tick all the boxes and is potentially more lucrative. What do I do?

Perhaps simplistic but...:)